Overview

Our MAGE-A10 T-cell therapy is directed to a highly immunogenic member of the MAGE-A family of cancer testis antigens expressed in a number of solid tumor cell types. Any expression in cancer is often associated with higher grade tumors.

Based on our ongoing preclinical evaluation, we believe our MAGE-A10 TCR therapeutic candidate has the potential ability to bind target peptides from multiple cancer types. Clinical trials to evaluate the safety and anti-tumor activity of our MAGE-A10 TCR therapy are open for certain patients with lung cancer, bladder, melanoma and head and neck cancers.

Pipeline

Candidate Indication Partner Development Stage
Research Pre-IND Phase 1/2
MAGE-A10 TCR NSCLC Wholly Owned
Research Phase complete
Pre-IND Phase complete
Phase 1/2 Phase in progress
Cohort 1: Study initiated in Q4 2015
Research Phase complete
Pre-IND Phase complete
Phase 1/2 Phase in progress
Bladder, Melanoma, and Head and Neck cancer Wholly Owned
Research Phase complete
Pre-IND Phase complete
Phase 1/2 Phase in progress

Learn More About